Linked Life Data

10600929

Source:http://linkedlifedata.com/resource/pubmed/id/10600929

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10600929rdf:typepubmed:Citationlld:pubmed
pubmed-article:10600929lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:10600929lifeskim:mentionsumls-concept:C0242643lld:lifeskim
pubmed-article:10600929lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:10600929lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:10600929lifeskim:mentionsumls-concept:C0525410lld:lifeskim
pubmed-article:10600929lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:10600929lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:10600929lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:10600929pubmed:issue6 Pt 2lld:pubmed
pubmed-article:10600929pubmed:dateCreated2000-1-19lld:pubmed
pubmed-article:10600929pubmed:abstractTextThe expression of two members of the ATP-binding cassette family of transport proteins, P-glycoprotein (P-gp) and the canalicular multispecific organic anion transporter (cMOAT or Mrp2), was evaluated in renal brush-border membranes (BBM) and various rat tissues after cisplatin treatment. One administration of cisplatin (5 mg/kg) increased P-gp expression by >200-300% in renal BBM and in crude membranes from liver and intestine. The increase in P-gp expression in the kidney was also detected in photolabeling experiments, suggesting the induction of functional P-gp. cMOAT expression was increased by >10-fold in renal BBM after cisplatin administration, although it had no effect on liver cMOAT expression. The increase in the levels of both proteins was maximal at 2 days after cisplatin treatment and lasted for at least 8 days. These results indicate that a single administration of cisplatin induces overexpression of P-gp and cMOAT in specific tissues. This may be of significant relevance to the design of clinical trials using cisplatin as a single chemotherapeutic agent or in combination with other drugs.lld:pubmed
pubmed-article:10600929pubmed:languageenglld:pubmed
pubmed-article:10600929pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10600929pubmed:citationSubsetIMlld:pubmed
pubmed-article:10600929pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10600929pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10600929pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10600929pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10600929pubmed:statusMEDLINElld:pubmed
pubmed-article:10600929pubmed:monthDeclld:pubmed
pubmed-article:10600929pubmed:issn0002-9513lld:pubmed
pubmed-article:10600929pubmed:authorpubmed-author:BrossardMMlld:pubmed
pubmed-article:10600929pubmed:authorpubmed-author:BéliveauRRlld:pubmed
pubmed-article:10600929pubmed:authorpubmed-author:DemeuleMMlld:pubmed
pubmed-article:10600929pubmed:issnTypePrintlld:pubmed
pubmed-article:10600929pubmed:volume277lld:pubmed
pubmed-article:10600929pubmed:ownerNLMlld:pubmed
pubmed-article:10600929pubmed:authorsCompleteYlld:pubmed
pubmed-article:10600929pubmed:paginationF832-40lld:pubmed
pubmed-article:10600929pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:meshHeadingpubmed-meshheading:10600929...lld:pubmed
pubmed-article:10600929pubmed:year1999lld:pubmed
pubmed-article:10600929pubmed:articleTitleCisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter.lld:pubmed
pubmed-article:10600929pubmed:affiliationLaboratoire de Médecine Moléculaire, Département de Chimie-Biochimie, Université du Québec à Montréal, Montreal, Quebec H3C 3P8, Canada.lld:pubmed
pubmed-article:10600929pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10600929pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
literatureCitation:1735_106...literatureCitation:pubmedpubmed-article:10600929lld:drugbank
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10600929lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10600929lld:pubmed